ArticleJournal of managed care & specialty pharmacy2023
Incremental cost burden among patients with severe uncontrolled asthma in the United States.
Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review.Lung · 2026Pooled it
- Post-genome-wide association study variant-to-function challenges in asthma research.The Journal of allergy and clinical immunology · 2026Review
- Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis.BMJ open respiratory research · 2026Article
- Pathogenic group 2 innate lymphoid cells as drivers of lung fibrosis in severe asthma.Frontiers in immunology · 2026Review
- Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1.Journal of asthma and allergy · 2026Article
- Burden of severe asthma in Italy: Patients treated with versus eligible for monoclonal antibodies in a large real-world study.The Journal of international medical research · 2026Article
- Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Evaluating Cost Savings Associated with a Patient-Facing Asthma Mobile Health Intervention.Applied clinical informatics · 2025Article
- The association between fruit and vegetable intake and the odds of asthma among children and adolescents.Journal of health, population, and nutrition · 2025Article
- Biologics in severe asthma: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial.ERJ open research · 2024Article
- Rate and predictors of biologic initiation in patients with severe asthma: a retrospective cohort study.Therapeutic advances in respiratory diseaseArticle
- What We Know to Date About Early Treatment With Biologics in Severe Asthma: A Scoping Review About the Use of Biologics in Severe Asthma and Possible Parallels With Early Rheumatoid Arthritis.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.